Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Share-based Compensation (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed Share-based Compensation for 11 consecutive years, with $34975.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Share-based Compensation changed 0.0% year-over-year to $34975.0, compared with a TTM value of $34975.0 through May 2025, down 74.97%, and an annual FY2024 reading of $139720.0, down 22.58% over the prior year.
  • Share-based Compensation was $34975.0 for Q3 2024 at CNBX Pharmaceuticals, up from $34795.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $728869.0 in Q3 2022 and bottomed at -$530662.0 in Q2 2022.
  • Average Share-based Compensation over 5 years is $70309.8, with a median of $34975.0 recorded in 2023.
  • Peak annual rise in Share-based Compensation hit 2865.37% in 2022, while the deepest fall reached 2056.43% in 2022.
  • Year by year, Share-based Compensation stood at $33000.0 in 2020, then surged by 1190.11% to $425737.0 in 2021, then tumbled by 82.25% to $75557.0 in 2022, then crashed by 53.71% to $34975.0 in 2023, then changed by 0.0% to $34975.0 in 2024.
  • Business Quant data shows Share-based Compensation for CNBX at $34975.0 in Q3 2024, $34795.0 in Q2 2024, and $34975.0 in Q1 2024.